Environmental-mediated drug resistance: a target for multiple myeloma therapy
Published 2009 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Environmental-mediated drug resistance: a target for multiple myeloma therapy
Authors
Keywords
-
Journal
Expert Review of Hematology
Volume 2, Issue 6, Pages 649-662
Publisher
Informa UK Limited
Online
2009-11-26
DOI
10.1586/ehm.09.55
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Celebrating the New
- (2017) Kimberly Callan Journal of the National Comprehensive Cancer Network
- RhoA and Rac1 GTPases play major and differential roles in stromal cell-derived factor-1-induced cell adhesion and chemotaxis in multiple myeloma
- (2009) A. K. Azab et al. BLOOD
- Vascular endothelial growth factor inhibition is not an effective therapeutic strategy for relapsed or refractory multiple myeloma: a phase 2 study of pazopanib (GW786034): Table 1
- (2009) H. Miles Prince et al. BLOOD
- Glucocorticoid resistance in a multiple myeloma cell line is regulated by a transcription elongation block in the glucocorticoid receptor gene (NR3C1)
- (2009) Beatriz Sánchez-Vega et al. BRITISH JOURNAL OF HAEMATOLOGY
- 1 Integrin Adhesion Enhances IL-6-Mediated STAT3 Signaling in Myeloma Cells: Implications for Microenvironment Influence on Tumor Survival and Proliferation
- (2009) K. H. Shain et al. CANCER RESEARCH
- Bortezomib, Dexamethasone, and Fibroblast Growth Factor Receptor 3-Specific Tyrosine Kinase Inhibitor in t(4;14) Myeloma
- (2009) G. Bisping et al. CLINICAL CANCER RESEARCH
- SDF-1alpha up-regulates interleukin-6 through CXCR4, PI3K/Akt, ERK, and NF-kappaB-dependent pathway in microglia
- (2009) Dah-Yuu Lu et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Recent advances in the systemic treatment of metastatic papillary renal cancer
- (2009) Simon Chowdhury et al. Expert Review of Anticancer Therapy
- Tandem Versus Single Autologous Hematopoietic Cell Transplantation for the Treatment of Multiple Myeloma: A Systematic Review and Meta-analysis
- (2009) A. Kumar et al. JNCI-Journal of the National Cancer Institute
- Dasatinib in relapsed or plateau-phase multiple myeloma
- (2009) Tanya M. Wildes et al. LEUKEMIA & LYMPHOMA
- The Fer Tyrosine Kinase Cooperates with Interleukin-6 to Activate Signal Transducer and Activator of Transcription 3 and Promote Human Prostate Cancer Cell Growth
- (2009) Amina Zoubeidi et al. MOLECULAR CANCER RESEARCH
- HYD1-induced increase in reactive oxygen species leads to autophagy and necrotic cell death in multiple myeloma cells
- (2009) R. R. Nair et al. MOLECULAR CANCER THERAPEUTICS
- Janus kinase inhibitor INCB20 has antiproliferative and apoptotic effects on human myeloma cells in vitro and in vivo
- (2009) R. Burger et al. MOLECULAR CANCER THERAPEUTICS
- A change of strategy in the war on cancer
- (2009) Robert A. Gatenby NATURE
- Engineered cystine knot peptides that bind αvβ3, αvβ5, and α5β1 integrins with low-nanomolar affinity
- (2009) Richard H. Kimura et al. PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS
- Validation of PDGFR and c-Src tyrosine kinases as tumor/vessel targets in patients with multiple myeloma: preclinical efficacy of the novel, orally available inhibitor dasatinib
- (2008) A. M. L. Coluccia et al. BLOOD
- Molecular basis of bortezomib resistance: proteasome subunit 5 (PSMB5) gene mutation and overexpression of PSMB5 protein
- (2008) R. Oerlemans et al. BLOOD
- Clonogenic Multiple Myeloma Progenitors, Stem Cell Properties, and Drug Resistance
- (2008) W. Matsui et al. CANCER RESEARCH
- Translating an Antagonist of Chemokine Receptor CXCR4: From Bench to Bedside
- (2008) D. Wong et al. CLINICAL CANCER RESEARCH
- Volociximab, a Chimeric Monoclonal Antibody that Specifically Binds 5 1 Integrin: A Phase I, Pharmacokinetic, and Biological Correlative Study
- (2008) A. D. Ricart et al. CLINICAL CANCER RESEARCH
- The Bone Marrow Microenvironment as a Tumor Sanctuary and Contributor to Drug Resistance
- (2008) M. B. Meads et al. CLINICAL CANCER RESEARCH
- CD44 and hyaluronan engagement promotes dexamethasone resistance in human myeloma cells
- (2008) Chikako Ohwada et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Altered Expression of Fibronectin and Collagens I and IV in Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance
- (2008) Tara M. Tancred et al. JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY
- On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia
- (2008) E J Feldman et al. LEUKEMIA
- Making progress in treating multiple myeloma with total therapies: issue of complete remission and more
- (2008) B Barlogie et al. LEUKEMIA
- The CXCR4 antagonist AMD3100 impairs survival of human AML cells and induces their differentiation
- (2008) S Tavor et al. LEUKEMIA
- Bone marrow microenvironment and the identification of new targets for myeloma therapy
- (2008) K Podar et al. LEUKEMIA
- New targets and treatments in multiple myeloma: Src family kinases as central regulators of disease progression
- (2008) Morie A. Gertz LEUKEMIA & LYMPHOMA
- Thalidomide Resistance Is Based on the Capacity of the Glutathione-Dependent Antioxidant Defense
- (2008) Jürgen Knobloch et al. MOLECULAR PHARMACEUTICS
- Canonical and non-canonical JAK–STAT signaling
- (2008) Willis X. Li TRENDS IN CELL BIOLOGY
- The multiple myeloma associated MMSET gene contributes to cellular adhesion, clonogenic growth, and tumorigenicity
- (2007) J. Lauring et al. BLOOD
- Dkk1-induced inhibition of Wnt signaling in osteoblast differentiation is an underlying mechanism of bone loss in multiple myeloma
- (2007) Ya-Wei Qiang et al. BONE
- Stem-Cell Transplantation for Multiple Myeloma in the Era of Novel Drugs
- (2007) William Bensinger JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started